AMICUS THERAPEUTICS INC. - COMMON STOCK

Amicus Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

01 мар 2022 07:00:02 Источник Nasdaq GlobeNewswire

Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates

24 фев 2022 07:00:02 Источник Nasdaq GlobeNewswire

Amicus Therapeutics to Announce Full-Year 2021 Financial Results on February 24, 2022

10 фев 2022 07:00:02 Источник Nasdaq GlobeNewswire

Amicus Therapeutics Announces Presentations and Posters at the 18th Annual WORLDSymposium™ 2022

07 фев 2022 07:00:01 Источник Nasdaq GlobeNewswire

Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance

10 янв 2022 07:00:02 Источник Nasdaq GlobeNewswire

Amicus Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

05 янв 2022 07:00:01 Источник Nasdaq GlobeNewswire

European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease

03 дек 2021 07:00:00 Источник Nasdaq GlobeNewswire

Amicus Therapeutics to Present at the 4th Annual Evercore ISI HealthCONx Virtual Conference

24 ноя 2021 07:00:00 Источник Nasdaq GlobeNewswire

Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism

22 ноя 2021 07:00:00 Источник Nasdaq GlobeNewswire

The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease

18 ноя 2021 07:00:01 Источник Nasdaq GlobeNewswire

Amicus Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference

11 ноя 2021 07:00:01 Источник Nasdaq GlobeNewswire

Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates

09 ноя 2021 07:00:04 Источник Nasdaq GlobeNewswire

Amicus Therapeutics to Announce Third Quarter 2021 Financial Results on November 9, 2021

03 ноя 2021 07:00:01 Источник Nasdaq GlobeNewswire

Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”

29 сен 2021 06:30:00 Источник Nasdaq GlobeNewswire

U.S. FDA Accepts Filings for Amicus’ AT-GAA for the Treatment of Pompe Disease

29 сен 2021 06:30:00 Источник Nasdaq GlobeNewswire

Amicus Therapeutics Announces Presentations at the 26th International Annual Congress of the World Muscle Society

20 сен 2021 07:00:00 Источник Nasdaq GlobeNewswire

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2021

03 сен 2021 07:00:00 Источник Nasdaq GlobeNewswire

Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease

02 авг 2021 07:00:00 Источник Nasdaq GlobeNewswire

Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021

27 июл 2021 07:00:00 Источник Nasdaq GlobeNewswire

Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors

14 июн 2021 07:00:00 Источник Nasdaq GlobeNewswire